Vincerx Pharma, Inc. (OTCPK: VINC)
Health Care · Biotechnology · US
$0.01
-15.89% today · -64.8% 1Y
Vincerx Pharma, Inc. (OTCPK: VINC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $66.47K and employs 13 people.
Over the last twelve months the share price has lost 64.8%, trading between 0.00 and 0.07.
Tweenvest scores Vincerx Pharma, Inc. across four factors: quality 26/100. Its strongest factor is quality.
VINC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $66.47K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -8.98
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- $0.07
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 5.23M
- Employees
- 13
- Next earnings
- —
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
- Founded
- 2019
- Listed since
- May 27, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.73 | -0.09% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.49 | +0.49% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.04 | -0.06% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.52 | -0.10% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.80 | -0.99% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $141.73 | -2.30% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.